002317.SZ
002317.SZ
CNE100000HW4
ZHONGSHENGYAOYE
Loading chart...

Company Profile

Guangdong Zhongsheng Pharmaceutical Co., Ltd. engages in research, development, production, and sale of pharmaceutical drugs in China. The company offers onradir, Leretevir, compound danshen, Cefixime Dispersible, Pyrazinamide, Ethamibutanol Hydrochloride, Ribavirin, loratadine, and isoniazid tablets; compound thromboplastin series, Zhong Sheng Wan series, and heat-clearing and dampness-removing granules products; NaoShuanTong, Cefadroxil, Rifampicin, and omeprazole enteric-coated capsules; carbocysteine, Ambroxol Hydrochloride, and Clomastine fumarate oral solutions; sucralfate oral suspension; reba pat film; and Azalastine Hydrochloride, Praprofen, Diquafosol Sodium, and Cyclosporine eye drops. It also focuses on the fields of respiratory antiviral, ophthalmology, cardiovascular and cerebrovascular endocrinology, anti-infection, digestion, and anti-allergy. Guangdong Zhongsheng Pharmaceutical Co., Ltd. was founded in 2001 and is headquartered in Dongguan, China.

Related stocks

300199.SZ
300199.SZ • China
HYBIO
23.71 CNY
3.13B USD 1Y +8.6%
2096.HK
2096.HK • China
SIMCERE PHARMA
10.89 HKD
3.56B USD 1Y -13.7%
688131.SS
688131.SS • China
SHANGHAI HAOYUAN CHEMEXPRESS CO
93.16 CNY
2.97B USD 1Y +9%
300142.SZ
300142.SZ • China
WALVAX
14.75 CNY
3.53B USD 1Y +26%
000623.SZ
000623.SZ • China
JLAD
17.53 CNY
3.14B USD 1Y -13.7%
300558.SZ
300558.SZ • China
BETTA
48.43 CNY
3.07B USD 1Y -29.3%
600518.SS
600518.SS • China
KANGMEI PHARMACEUTICAL CO LTD
1.35 CNY
2.79B USD 1Y -33.8%
300601.SZ
300601.SZ • China
KANGTAI BIOLOGICAL
13.44 CNY
2.25B USD 1Y -20.6%

Key Metrics & Overview

Detailed metrics & financial data of the company

Company Profile
5 Metrics

🛡️ Risk & Structural Analysis

Multi-Factor Risk Model & Market Data

7/7 Very High
5Y Volatility
58.3% p.a.
Max Drawdown (5Y)
-73.6%
Sharpe Ratio (5Y)
0.30
Beta Factor
0.63
Size Class
Large Cap
Notes & Warnings
Single Stock Risk: Investing in an individual stock carries full company and insolvency risk (no fund diversification).
Exemplary balance sheet strength: Very solid ratio of equity to debt.
🔴 High valuation risk: Avg P/E of 98.0 (Elevated multiple compression risk)
🔴 Low analyst coverage – higher uncertainty in growth estimates & projections
Structurally High Volatility: Above-average fluctuations persist across 5 to 10 years (58.3% p.a.).
Historical Stress Test: Maximum peak-to-trough drawdown of -73.6% in the extended horizon.
ende